Hi Edgar, Thank you for sharing these thoughtful insights and practical examples from your experience in rare and orphan disease trials. Your point about involving patient advocacy groups early in protocol design is especially interesting, particularly ...

Hi Rachana, Thank you for sharing these insights. The point about shifting from vendor "management" to true partnership is especially valuable in rare disease trials, where operational success often depends on close alignment across multiple stakeholders. ...

Hi Julia, Typically "complete" in ALCOA means the completeness of the individual note; were things removed/deleted, is critical data that should exist absent, and not necessarily the chart as a whole. ALCOA helps answer the question - is this record ...